

Send us your news to evbc@uni-jena.de.

For more frequent updates, please follow us on Twitter [@EVirusBioinfC](#).

Recent Selected Publications on SARS-CoV-2 by EVBC Members

Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity. *Immunity*

[10.1016/j.immuni.2021.01.017](https://doi.org/10.1016/j.immuni.2021.01.017)

Next-generation diagnostics: virus capture facilitates a sensitive viral diagnosis for epizootic and zoonotic pathogens including SARS-CoV-2. Now published in *Microbiome* [10.1186/s40168-020-00973-z](https://doi.org/10.1186/s40168-020-00973-z)

CoronaHiT: high-throughput sequencing of SARS-CoV-2 genomes. *Genome Med* [10.1186/s13073-021-00839-5](https://doi.org/10.1186/s13073-021-00839-5)

Effects of Social Distancing Measures during the First Epidemic Wave of Severe Acute Respiratory Syndrome Infection, Greece. Now published in *Emerg Infect Dis* [10.3201/eid2702.203412](https://doi.org/10.3201/eid2702.203412)

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses. *Front Immunol* [10.3389/fimmu.2020.628971](https://doi.org/10.3389/fimmu.2020.628971)

Differentially conserved amino acid positions may reflect differences in SARS-CoV-2 and SARS-CoV behaviour. *Bioinformatics* [10.1093/bioinformatics/btab094](https://doi.org/10.1093/bioinformatics/btab094)

Clinical, virological and immunological features of a mild case of SARS-CoV-2 re-infection. *Clin Microbiol Infect* [10.1016/j.cmi.2021.02.010](https://doi.org/10.1016/j.cmi.2021.02.010)

AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. *Antimicrob Agents Chemother* [10.1128/AAC.02479-20](https://doi.org/10.1128/AAC.02479-20)

Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy. *iScience* [10.1016/j.isci.2021.102151](https://doi.org/10.1016/j.isci.2021.102151)

Generalized linear models provide a measure of virulence for specific mutations in SARS-CoV-2 strains. *PLoS One* [10.1371/journal.pone.0238665](https://doi.org/10.1371/journal.pone.0238665)

SARS-CoV-2 Re-infections: Lessons from Other Coronaviruses. *Med* [10.1016/j.medj.2020.12.005](https://doi.org/10.1016/j.medj.2020.12.005)

Prospective surveillance study in a 1,400-bed university hospital: COVID-19 exposure at home was the main risk factor for SARS-CoV-2 point seroprevalence among hospital staff. *Transbound Emerg Dis* [10.1111/tbed.14041](https://doi.org/10.1111/tbed.14041)

Reviews

Potential APOBEC-mediated RNA editing of the genomes of SARS-CoV-2 and other coronaviruses and its impact on their longer term evolution. *Virology* [10.1016/j.virol.2020.12.018](https://doi.org/10.1016/j.virol.2020.12.018)

Preprints

SARS-CoV-2 European resurgence foretold: interplay of introductions and persistence by leveraging genomic and mobility data. *Research Square* [10.21203/rs.3.rs-208849/v1](https://doi.org/10.21203/rs.3.rs-208849/v1)

Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2. *medRxiv* [10.1101/2021.02.08.21251329](https://doi.org/10.1101/2021.02.08.21251329)

A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic. *medRxiv* [10.1101/2021.02.08.21251393](https://doi.org/10.1101/2021.02.08.21251393)

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2. *bioRxiv* [10.1101/2021.01.26.428207](https://doi.org/10.1101/2021.01.26.428207)

Molecular epidemiology of SARS-CoV-2 in Greece reveals low rates of onward virus transmission after lifting of travel restrictions based on risk assessment during summer 2020. *medRxiv* [10.1101/2021.01.31.21250868](https://doi.org/10.1101/2021.01.31.21250868)

In vitro evolution of Remdesivir resistance reveals genome plasticity of SARS-CoV-2. *bioRxiv* [10.1101/2021.02.01.429199](https://doi.org/10.1101/2021.02.01.429199)

Molecular epidemiology of SARS-CoV-2 – a regional to global perspective. *medRxiv* [10.1101/2021.01.25.21250447](https://doi.org/10.1101/2021.01.25.21250447)

PCR assay to enhance global surveillance for SARS-CoV-2 variants of concern. *medRxiv* [10.1101/2021.01.28.21250486](https://doi.org/10.1101/2021.01.28.21250486)

Detection Of Genomic Variants Of SARS-CoV-2 Circulating In Wastewater By High-Throughput Sequencing. *bioRxiv* [10.1101/2021.02.08.21251355](https://doi.org/10.1101/2021.02.08.21251355)

CovRadar: Continuously tracking and filtering SARS-CoV-2 mutations for molecular surveillance. *bioRxiv* [10.1101/2021.02.03.429146](https://doi.org/10.1101/2021.02.03.429146)

Viral genetic sequencing identifies staff transmission of COVID-19 is important in a community hospital outbreak. *medRxiv* [10.1101/2021.02.18.21250737](https://doi.org/10.1101/2021.02.18.21250737)

Limited specificity of SARS-CoV-2 antigen-detecting rapid diagnostic tests at low temperatures. *medRxiv* [10.1101/2021.02.01.21250904](https://doi.org/10.1101/2021.02.01.21250904)

Longitudinal omics in Syrian hamsters integrated with human data unravel cellular effector responses to moderate COVID-19. *Research Square* [10.21203/rs.3.rs-148392/v1](https://doi.org/10.21203/rs.3.rs-148392/v1)

 [EVBC publications on SARS-CoV-2](#)

SARS-CoV-2 Bioinformatics Tools and Resources

We are very happy to announce our revised and redesigned [collection of virus bioinformatics tools](#). Don't hesitate to contact us if you want a tool to be added or require any further features for this collection. We strongly encourage you to leave comments and/or send us feedback on the tools.

– [CovRadar](#) for tracking and filtering SARS-CoV-2 mutations for molecular surveillance.

 [Coronavirus tools website](#)